Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
zandatrigine
- Development stage
- Phase 2
- Lead developer
- Neurocrine Biosciences
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**Zandatrigine** (also known as NBI-921352 or XEN901) is a highly selective small molecule inhibitor of the voltage-gated sodium channel **Nav1.6** (SCN8A), designed to reduce neuronal hyperexcitability and epileptic seizures. It demonstrates 134-756-fold selectivity over other sodium channel isoforms such as NaV1.1. Originally developed by Xenon Pharmaceuticals, it is now being advanced by Neurocrine Biosciences primarily for **SCN8A developmental and epileptic encephalopathy (SCN8A-DEE)**, a rare pediatric epilepsy, as an oral adjunctive therapy to existing anti-seizure medications.[1][2][3][5]
- Other names
- zandatrigine
02
Targets
SCN8A (NaV1.6)
Beyond the preview
Go deeper on zandatrigine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on zandatrigine.